Investor/Media Center

Press Releases


 
Jan 6, 2016 Bio-Path Holdings to Present at Biotech Showcase™ 2016
Dec 8, 2015

Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting

Two of the three evaluable patients achieved complete remission in safety segment of the Phase II combination therapy trial of BP1001 (Liposomal Grb2 antisense)

Nov 10, 2015 Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results
Nov 5, 2015 Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting
Oct 13, 2015 Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum
Oct 9, 2015 Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia
Sep 2, 2015 Bio-Path Holdings To Present at the 17th Annual Rodman & Renshaw Global Investment Conference
Aug 31, 2015 Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers
Aug 11, 2015 Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results
Jun 25, 2015 Bio-Path Holdings Announces "At the Market" Offering with Cantor Fitzgerald
May 12, 2015 Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results
Apr 28, 2015 Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia
Apr 24, 2015 Letter to Shareholder from President and CEO
Apr 22, 2015 Bio-Path Holdings' Drug Delivery Technology to be Featured in a Presentation at IBC's 17th Annual TIDES Oligoneucleotide and Peptide Therapeutics Conference
Mar 17, 2015 Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results
Mar 5, 2015 Letter to Shareholder from President and CEO
Feb 9, 2015 Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients
Jan 7, 2015 Bio-Path Holdings' Liposomal Grb-2 Featured in Peer-Reviewed Journal "Expert Opinion on Drug Delivery"
Jan 6, 2015 Bio-Path Holdings to Present at the Biotech Showcase 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time
Dec 22, 2014 Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma - Company Broadening its Pipeline with Second Product Candidate -
Nov 17, 2014 Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results
Nov 6, 2014 Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors
Oct 16, 2014 NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, October 17, 2014 at 3:45 - 4:00 PM Eastern Time)
Oct 7, 2014 Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers
Sep 30, 2014 Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday October 7, 2014 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)
Aug 18, 2014 Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results
Jun 30, 2014 Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes
Jun 19, 2014 Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial
May 19, 2014 Bio-Path Holdings Reports First Quarter 2014 Operational and Financial Results
Apr 1, 2014 Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results
Mar 26, 2014 Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer
Mar 5, 2014 Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market
Jan 16, 2014 Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering
Jan 7, 2014 Bio-Path Holdings to Present at the Biotech Showcase 2014 Conference in San Francisco, CA on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time
Dec 9, 2013 Preliminary Results from Bio-Path Holdings' Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
Nov 15, 2013 Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results
Nov 7, 2013 Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting: Data Suggests Potential for AML and MDS Disease Inhibition with Liposomal Grb-2-
Oct 1, 2013 Bio-Path Holdings to Present at the 12th Annual BIO Investor Forum
Sep 19, 2013 Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC
Aug 15, 2013 Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results
Aug 9, 2013 Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics
Jul 22, 2013 Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers
Jun 6, 2013 Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
May 16, 2013 Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results
Apr 2, 2013 Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results
Mar 7, 2013 Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
Jan 3, 2013 Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time
Dec 6, 2012 Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers
Nov 16, 2012 Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results
Nov 14, 2012 Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Oct 4, 2012 Bio-Path Holdings Adds New Board Member
Oct 3, 2012 Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)

Webcast link here.

Sep 4, 2012 Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference
Aug 24, 2012 Bio-Path Holdings to Present at the 2012 Southern California Investor Conference
Webcast Link Here
Aug 16, 2012 Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results
Jul 25, 2012 Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
Jun 4, 2012 Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market
May 29, 2012 Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
May 17, 2012 Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results - Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2
Apr 3, 2012 Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
Mar 29, 2012 Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program
Feb 7, 2012 Bio-Path Holdings Successfully Completes Second Cohort in
Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Jan 4, 2012 Bio-Path Holdings to Present at Biotech Showcase 2012 Conference
Dec 13, 2011 Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose
Nov 15, 2011 Press Release Form 8-K - 3rd Quarter Financial Results
Oct 24, 2011 Proxy Statement fothereer 2011
Oct 19, 2011 Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time
Oct 4, 2011 Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting
Sep 6, 2011 Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference 
Link to Conference on September 13, 2011 at 4:55 pm Eastern Time
Aug 11, 2011 First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Jul 27, 2011 Bio-Path recently featured in Genomeweb/Gene Silencing News
May 17, 2011 Bio-Path Holdings Reports First Quarter 2011 Financial Results
Apr 28, 2011 Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research
Apl 4, 2011 Zack's Small-Cap Research Release
Mar 31, 2011 Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results
Feb 23, 2011 CEOCFO Interviews Peter H. Nielsen, CEO
Feb 23, 2011 Zack's Small-Cap Research Release
Nov 15, 2010 Bio-Path Holdings Reports Third Quarter 2010 Financial Results
Nov 3, 2010 Bio-Path Holdings Awarded Grant From The U.S. Government's Qualifying Therapeutic Discovery Project Program
Aug 17, 2010 Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results
Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital 
Jul 29, 2010 Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate
Jun 4, 2010 Bio-Path Holdings Signs Equity Financing Deal
Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital

Mar 12, 2010 FDA Allows IND For Bio-Path Holdings' Liposomal Grb-2
Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS
 
Dec 14, 2009 Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status  
Nov 2, 2009 Bio-Path Holdings, Inc. Operations Update
Sep 22, 2009 Bio-Path Holdings, Inc. Announces Plans To Develop
Liposome Tumor Targeting Technology Licensed from The
University of Texas M. D. Anderson Cancer Center
Jun 23, 2009 Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology
Jun 6, 2009   Proxy Statement and Proxy
Apr 14, 2009 Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial  
Dec 10, 2008 Letter To Shareholders
Dec 3, 2008 Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program
Nov 17, 2008 Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.
Mar 3, 2008 Bio-Path Becomes a Publicly Traded Company